Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: A prospective randomized multicentre trial

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 232-239

  Hetzel, Gerd R ^a   Schmitz, Michael ^a   Wissing, Heimo ^b   Ries, Wolfgang ^c   Schott, Gabriele ^d   Heering, Peter J ^e   Isgro, Frank ^f   Kribben, Andreas ^g   Himmele, Rainer ^h   Grabensee, Bernd ^a   Rump, Lars C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Diakonissen Hospital Flensburg   (Germany)

^d Helios Hospital Krefeld   (Germany)

^e General Hospital Solingen   (Germany)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h Fresenius Medical Care ^*  (Germany)

Author keywords

acute renal failure; anticoagulation; citrate; haemofiltration

Indexed keywords

BICARBONATE; CITRIC ACID; HEPARIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTICOAGULATION; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; AGED; ANTICOAGULANTS; BICARBONATES; BUFFERS; CITRATES; CRITICAL ILLNESS; FEMALE; HEMOFILTRATION; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78650636539     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq575     Document Type: Article

References (20)

1. Liaño F, Junco E, Pascual J et al. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. Kidney Int Suppl 1998; 66: S16-S24
2. McCarthy JT. Prognosis of patients with acute renal failure in the intensive care unit: a tale of two eras. Mayo Clin Proc 1996; 71: 117-126
3. Metnitz PG, Krenn CG, Steltzer H et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002; 30: 2051-2058
4. Uchino S, Kellum JA, Bellomo R et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-818
5. Lins RL, Elseviers MM, van der Niepen P et al. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomised clinical trial. Nephrol Dial Transplant 2009; 24: 512-518
6. Palevsky PM et al. VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359: 7-20
7. RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361: 1627-1638
8. Böhler J, Schollmeyer P, Dressel B et al. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutro-phil degranulation. J Am Soc Nephrol 1996; 7: 234-241
9. Gritters M, Grooteman MP, Schoorl M et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006; 21: 153-159
10. Oudemans-van Straaten HM, Bosman RJ, Koopmans M et al. Citrate anticoagulation for continuous venovenous haemofiltration. Crit Care Med 2009; 37: 545-552
11. Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11: 218
12. Morgera S, Schneider M, Slowinski T et al. A safe citrate anticoagu-lation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009; 37: 2018-2024
13. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous haemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55: 1991-1997
14. Schmitz M, Taskaya G, Plum J et al. Continuous venovenous haemo-filtration using a citrate buffered substitution fluid. Anaesth Intensive Care 2007; 35: 529-535
15. Ronco C, Bellomo R, Homel P et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356: 26-30
16. Barenbrock M, Hausberg M, Matzkies F et al. Effects of bicarbonate-and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients. Kidney Int 2000; 58: 1751-1757
17. Mehta RL, McDonald BR, Aguilar MM et al. Regional citrate antic-oagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38: 976-981
18. Betjes MG, van Oosterom D, van Agteren M et al. Regional citrate versus heparin anticoagulation during venovenous haemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol 2007; 20: 602-608
19. Kutsogiannis DJ, Gibney RT, Stollery D et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367
20. Monchi M, Berghmans D, Ledoux D et al. Citrate vs. heparin for anticoagulation in continuous venovenous haemofiltration: a prospective randomised study. Intensive Care Med 2004; 30: 260-265